Cas no 1191-87-3 (2,5,8,11,14,17-Hexaoxaoctadecane)

2,5,8,11,14,17-Hexaoxaoctadecane is a polyethylene glycol (PEG)-based compound featuring a linear hexaether structure with six oxygen atoms integrated into an 18-carbon chain. This structure imparts high solubility in polar solvents, making it useful as a phase-transfer catalyst or solubilizing agent in organic synthesis. Its ether linkages provide flexibility and stability under mild reaction conditions, while its amphiphilic nature enhances compatibility with both aqueous and organic phases. The compound is particularly valued for its role in modifying reaction kinetics and improving reagent accessibility in heterogeneous systems. Its well-defined molecular weight and purity ensure consistent performance in specialized applications, such as polymer chemistry and material science.
2,5,8,11,14,17-Hexaoxaoctadecane structure
1191-87-3 structure
Product Name:2,5,8,11,14,17-Hexaoxaoctadecane
CAS No:1191-87-3
MF:C12H26O6
MW:266.331244945526
MDL:MFCD00055429
CID:141596
PubChem ID:70931
Update Time:2025-10-20

2,5,8,11,14,17-Hexaoxaoctadecane Chemical and Physical Properties

Names and Identifiers

    • 2,5,8,11,14,17-Hexaoxaoctadecane
    • Pentaethyleneglycol dimethyl ether
    • 1,14-dimethoxy-3,6,9,12-tetraoxa-tetradecane
    • 1-methoxy-2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethane
    • pentaglyme
    • Pentaethylene glycol dimethyl ether (Pentaglyme)
    • 1191-87-3
    • Q27093554
    • DMDPGPKXQDIQQG-UHFFFAOYSA-N
    • BAA19187
    • 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE
    • CHEBI:44934
    • SCHEMBL124091
    • EINECS 214-743-5
    • AS-76354
    • DTXSID80152319
    • NSC244990
    • NSC-244990
    • AKOS025396478
    • B0001-283024
    • NS00041929
    • DB02580
    • NSC 244990
    • CS-0442132
    • 2,8,11,14,17-Hexaoxaoctadecane
    • DB-292276
    • DTXCID3074810
    • A10939
    • 1-(2-METHOXY-ETHOXY)-2-(2-(2-(2-METHOXY-ETHOXY)-ETHOXY)-ETHANE
    • MDL： MFCD00055429
    • Inchi： 1S/C12H26O6/c1-13-3-5-15-7-9-17-11-12-18-10-8-16-6-4-14-2/h3-12H2,1-2H3
    • InChI Key： DMDPGPKXQDIQQG-UHFFFAOYSA-N
    • SMILES： O(CCOCCOC)CCOCCOCCOC

Computed Properties

  • Exact Mass: 266.17298
  • Monoisotopic Mass: 266.173
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 0
  • Hydrogen Bond Acceptor Count: 6
  • Heavy Atom Count: 18
  • Rotatable Bond Count: 15
  • Complexity: 129
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: nothing
  • XLogP3: nothing
  • Topological Polar Surface Area: 55.4A^2

Experimental Properties

  • Density: 1.005
  • Boiling Point: 314.2°C at 760 mmHg
  • Flash Point: 118.2°C
  • Refractive Index: 1.427
  • PSA: 55.38

2,5,8,11,14,17-Hexaoxaoctadecane Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Alichem
A449038969-250mg
2,5,8,11,14,17-Hexaoxaoctadecane
 1191-87-3 95%
250mg
 $300.00 2023-09-04
Alichem
A449038969-1g
2,5,8,11,14,17-Hexaoxaoctadecane
 1191-87-3 95%
1g
 $832.50 2023-09-04
eNovation Chemicals LLC
D582309-1g
2,5,8,11,14,17-hexaoxaoctadecane
 1191-87-3 95%
1g
 $525 2025-02-20
eNovation Chemicals LLC
D543331-5g
2,5,8,11,14,17-hexaoxaoctadecane
 1191-87-3 95%
5g
 $2400 2025-02-19
eNovation Chemicals LLC
D543331-1g
2,5,8,11,14,17-hexaoxaoctadecane
 1191-87-3 95%
1g
 $750 2025-02-19
1PlusChem
1P000IO2-50mg
2,5,8,11,14,17-Hexaoxaoctadecane
 1191-87-3 95%
50mg
 $99.00 2023-12-26
1PlusChem
1P000IO2-100mg
2,5,8,11,14,17-Hexaoxaoctadecane
 1191-87-3 95%
100mg
 $145.00 2023-12-26
1PlusChem
1P000IO2-250mg
2,5,8,11,14,17-Hexaoxaoctadecane
 1191-87-3 95%
250mg
 $242.00 2023-12-26
1PlusChem
1P000IO2-1g
2,5,8,11,14,17-Hexaoxaoctadecane
 1191-87-3 95%
1g
 $676.00 2023-12-26
A2B Chem LLC
AA23394-100mg
2,5,8,11,14,17-Hexaoxaoctadecane
 1191-87-3 95%
100mg
 $121.00 2024-04-20

2,5,8,11,14,17-Hexaoxaoctadecane Related Literature

Additional information on 2,5,8,11,14,17-Hexaoxaoctadecane

Recent Advances in the Study of 2,5,8,11,14,17-Hexaoxaoctadecane (CAS: 1191-87-3) and Its Applications in Chemical Biology and Medicine

The compound 2,5,8,11,14,17-Hexaoxaoctadecane (CAS: 1191-87-3), a polyethylene glycol (PEG) derivative, has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This research brief aims to synthesize the latest findings on this compound, focusing on its structural properties, synthetic methodologies, and emerging applications in drug delivery, bioconjugation, and biomedical engineering.

Recent studies have highlighted the unique physicochemical properties of 2,5,8,11,14,17-Hexaoxaoctadecane, including its high solubility in aqueous and organic solvents, biocompatibility, and low immunogenicity. These attributes make it an ideal candidate for modifying therapeutic agents, enhancing their pharmacokinetic profiles, and reducing systemic toxicity. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in improving the half-life of peptide-based drugs through PEGylation, a technique that involves the covalent attachment of PEG chains to bioactive molecules.

In the realm of bioconjugation, 2,5,8,11,14,17-Hexaoxaoctadecane has been employed as a linker molecule to facilitate the attachment of targeting ligands to nanoparticles or antibodies. A groundbreaking study in ACS Nano (2023) showcased its role in the development of targeted drug delivery systems for cancer therapy, where the compound's ability to form stable conjugates with both hydrophobic and hydrophilic moieties was leveraged to enhance tumor-specific accumulation of chemotherapeutic agents.

Furthermore, advancements in synthetic chemistry have enabled the precise control over the molecular weight and polydispersity of 2,5,8,11,14,17-Hexaoxaoctadecane, addressing previous challenges related to batch-to-batch variability. A 2024 report in Angewandte Chemie detailed a novel enzymatic polymerization technique that yields monodisperse PEG derivatives, including 1191-87-3, with unprecedented precision. This innovation is expected to accelerate the translation of PEGylated therapeutics from bench to bedside.

Despite these promising developments, challenges remain in optimizing the biocompatibility and biodegradability of 2,5,8,11,14,17-Hexaoxaoctadecane-based formulations. Recent research in Biomaterials Science (2024) has explored the use of alternative PEG architectures and co-polymers to mitigate potential immune responses and improve metabolic clearance. These efforts underscore the ongoing need for interdisciplinary collaboration to fully realize the potential of this compound in clinical settings.

In conclusion, 2,5,8,11,14,17-Hexaoxaoctadecane (CAS: 1191-87-3) continues to be a cornerstone of innovation in chemical biology and medicine. Its applications in drug delivery, bioconjugation, and biomedical engineering are expanding rapidly, driven by advances in synthetic methodologies and a deeper understanding of its biological interactions. Future research should focus on addressing remaining challenges related to biocompatibility and scalability to unlock its full therapeutic potential.

1191-87-3 (2,5,8,11,14,17-Hexaoxaoctadecane) Related Products

Recommended suppliers
上海嶸奧生物技術(shù)有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
上海嶸奧生物技術(shù)有限公司
Shandong Feiyang Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Feiyang Chemical Co., Ltd
Hangzhou Cedareal Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hangzhou Cedareal Technology Co., Ltd.
Shanghai Jinhuan Chemical CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shanghai Jinhuan Chemical CO., LTD.
Shenzhen Yaoyuan R&D Center Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Yaoyuan R&D Center Co.,Ltd